Efficacy of camrelizumab in combination with lenvatinib in treatment of patients with advanced liver cancer and its impact on T lymphocyte subsets
Objective To investigate the synergy of camrelizumab and lenvatinib in treating advanced hepatocellular carcinoma and evaluate its influence on T lymphocyte subsets.Methods This study selected 86 patients with advanced liver cancer admitted to Shaanxi Nuclear Industry 215 Hospital from August 2021 to June 2022 as the subjects.These patients were divided into a monitoring group and a comparative group using a random number table,with 43 patients in each group.The patients in the control group were treated with lenvatinib while those in the observation group received therapy with camrelizumab in addition to lenvatinib.The clinical effectiveness,T lymphocyte subsets(encompassing the proportions of CD3+,CD4+,CD8+as well as the CD4+/CD8+)and the frequency of adverse events were compared between the two groups.Results The observation group achieved a disease control rate of 79.07%,which was higher than the control group's rate of 53.49%(χ2=6.295,P<0.05).However,no significant difference was found in the objective response rate between the two groups(55.81%vs 37.21%,χ2=2.991,P>0.05).After treatment,the percentages of CD3+,CD4+and the CD4+/CD8+in the observation group were(72.78±7.21)%,(47.34±6.21)%and(1.98±0.45),respectively,which were higher than those in the control((63.45±6.88)%,(37.02±5.02)%and(1.41±0.32),(t=6.139,8.475,6.769,all P<0.05).The observation group exhibited a lower percentage of CD8+as compared with the control((22.43±2.11)%vs(25.86±2.89)%,t=6.286,P<0.05).No statistically significant difference was found in the frequency of adverse reactions between the two groups(11.63%vs 23.26%,χ2=2.019,P>0.05).Conclusion Camrelizumab in combination with lenvatinib is effective in the treatment of advanced liver cancer because it can restore the balance of T-lymphocyte subsets,improve the immune function and has a high safety profile.
NETL
NSTL
万方数据
